Cardiovascular Innovation Institute and the Department of Physiology, University of Louisville, Louisville, Kentucky.
Department of Bioengineering, University of Louisville, Louisville, Kentucky.
Am J Physiol Heart Circ Physiol. 2022 Apr 1;322(4):H647-H680. doi: 10.1152/ajpheart.00674.2021. Epub 2022 Feb 18.
Pathologies of the vasculature including the microvasculature are often complex in nature, leading to loss of physiological homeostatic regulation of patency and adequate perfusion to match tissue metabolic demands. Microvascular dysfunction is a key underlying element in the majority of pathologies of failing organs and tissues. Contributing pathological factors to this dysfunction include oxidative stress, mitochondrial dysfunction, endoplasmic reticular (ER) stress, endothelial dysfunction, loss of angiogenic potential and vascular density, and greater senescence and apoptosis. In many clinical settings, current pharmacologic strategies use a single or narrow targeted approach to address symptoms of pathology rather than a comprehensive and multifaceted approach to address their root cause. To address this, efforts have been heavily focused on cellular therapies and cell-free therapies (e.g., exosomes) that can tackle the multifaceted etiology of vascular and microvascular dysfunction. In this review, we discuss ) the state of the field in terms of common therapeutic cell population isolation techniques, their unique characteristics, and their advantages and disadvantages, ) common molecular mechanisms of cell therapies to restore vascularization and/or vascular function, ) arguments for and against allogeneic versus autologous applications of cell therapies, ) emerging strategies to optimize and enhance cell therapies through priming and preconditioning, and, finally, ) emerging strategies to bolster therapeutic effect. Relevant and recent clinical and animal studies using cellular therapies to restore vascular function or pathologic tissue health by way of improved vascularization are highlighted throughout these sections.
血管病理学包括微血管病理学,其性质通常较为复杂,导致血管通畅性和适当灌注的生理稳态调节丧失,无法满足组织代谢需求。微血管功能障碍是大多数衰竭器官和组织病理学的一个关键潜在因素。导致这种功能障碍的病理因素包括氧化应激、线粒体功能障碍、内质网(ER)应激、内皮功能障碍、血管生成潜力和血管密度丧失,以及衰老和细胞凋亡增加。在许多临床情况下,当前的药物治疗策略采用单一或狭窄的靶向方法来解决病理学症状,而不是采用全面和多方面的方法来解决其根本原因。为了解决这个问题,人们已经大力专注于细胞疗法和无细胞疗法(例如外泌体),这些疗法可以解决血管和微血管功能障碍的多方面病因。在这篇综述中,我们讨论了)常见治疗性细胞群体分离技术的领域现状,包括它们的独特特征及其优缺点,)细胞疗法恢复血管生成和/或血管功能的常见分子机制,)同种异体与自体细胞疗法应用的优缺点,)通过启动和预处理来优化和增强细胞疗法的新兴策略,以及,)增强治疗效果的新兴策略。通过改善血管生成来恢复血管功能或病理性组织健康的细胞疗法的相关和最近的临床和动物研究在这些部分中得到了强调。